Six top biotech VCs take a look at the latest trends, and offer their thoughts on 2018
This year has been a relative gusher of VC dollars flowing into biotech companies, with giant “mega-deals” propelling the industry’s record-setting year. Top VCs in the field say they’re cautiously optimistic that the trend will continue next year.
The industry has cruised past its previous VC funding record of $7.3 billion, which was set back in 2015. This year saw biotechs raise $9.3 billion in 471 deals, according to PitchBook, making it the best year out of the last seven when it comes to volume.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.